The use of megavoltage radiation therapy in the treatment of thymomas in rabbits: 19 cases [0.03%]
兔恶性胸腺瘤的放射治疗病例报告
K M Andres,M Kent,C T Siedlecki et al.
K M Andres et al.
An overall median survival time (MST) and prognostic factors in rabbits with thymomas treated with megavoltage radiation therapy (RT) were determined in this multi-institutional retrospective case analysis. Medical records for 19 rabbits wi...
Multimodal therapeutic approach and interdisciplinary challenge for the treatment of unresectable head and neck squamous cell carcinoma in six cats: a pilot study [0.03%]
六只猫不可切除的头部和颈部鳞状细胞癌的多模式治疗方法及跨学科挑战：一项初步研究
L Marconato,J Buchholz,M Keller et al.
L Marconato et al.
Feline head and neck squamous cell carcinoma (SCC) is a loco-regional disease harbouring a poor prognosis. The complex anatomic location precludes aggressive surgical resection and tumours recur within weeks to few months. Response to chemo...
A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs [0.03%]
一项在狗身上寻找剂量的新型水溶性紫杉醇配方治疗恶性高级别实体瘤的研究
H von Euler,P Rivera,H Nyman et al.
H von Euler et al.
A new formulation of water-soluble paclitaxel (Paccal® Vet) has been developed for canine cancer patients, without the need for pre-medication (traditionally required in non-water-soluble paclitaxel formulations). The objective of the stud...
Epithelial-mesenchymal transition as a fundamental mechanism underlying the cancer phenotype [0.03%]
上皮间质转化是癌症表型的基础机制
A Cervantes-Arias,L Y Pang,D J Argyle
A Cervantes-Arias
Epithelial-mesenchymal transition (EMT) is a complex process involved in embryonic development, wound healing and carcinogenesis. During this process, epithelial cells lose their defining characteristics and acquire mesenchymal properties: ...
Diagnostic evaluation and treatment recommendations for dogs with substage-a high-grade multicentric lymphoma: results of a survey of veterinarians [0.03%]
关于亚A期高等级多中心淋巴瘤犬的诊断评估及治疗建议：兽医师调查结果
R C Regan,M S W Kaplan,D B Bailey
R C Regan
The goal of this study was to survey veterinarians regarding their current initial diagnostic and treatment recommendations for dogs with substage-a high-grade multicentric lymphoma. A written survey was conducted at the 2009 Veterinary Can...
Histopathological and immunohistochemical studies of apocrine sweat gland adenocarcinomas in cats [0.03%]
猫顶泌汗腺腺癌的病理组织学和免疫组化研究
R Haziroglu,M Haligur,H Keles
R Haziroglu
Seven adenocarcinomas of apocrine sweat glands among the 67 cutaneous tumours of cats were evaluated between 1980 and 2005. Histopathologically, three tumours were solid, tubular, tubular-ductal, tubular-cystic and papillar-cystic types wer...
Serum vascular endothelial growth factor in dogs with soft tissue sarcomas [0.03%]
血管内皮生长因子在患有软组织肉瘤的犬血清中的检测
G Fernandes de Queiroz,M Lúcia Zaidan Dagli,S Aparecida Meira et al.
G Fernandes de Queiroz et al.
This work aimed to evaluate serum vascular endothelial growth factor (VEGF) in 25 dogs with soft tissue sarcoma, and in 30 healthy dogs. Blood was collected once time from the control animals and three times, in the same way, from animals w...
M W Campbell,P R Hess,L E Williams
M W Campbell
There is little information regarding the presentation, biologic behaviour, treatment and prognosis in cats with chronic lymphocytic leukaemia (CLL), and further investigation is needed to characterize this disease in cats. The goal of this...
Epirubicin as part of a multi-agent chemotherapy protocol for canine lymphoma [0.03%]
表柔比星联合化疗治疗犬淋巴瘤
J W Elliott,P Cripps,A M Marrington et al.
J W Elliott et al.
The aim of the study was to report the outcome of treatment of 97 dogs with lymphoma that received a multi-agent chemotherapy protocol containing epirubicin as the primary anthracycline. Seventy-five dogs received a 25-week protocol with no...
Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs [0.03%]
罗格列酮口服联合顺铂静脉注射治疗携带肿瘤的狗的I期临床试验
S Allstadt Frazier,D S McKemie,T A Guerrero et al.
S Allstadt Frazier et al.
Rosiglitazone is an FDA-approved peroxisome proliferator-activated receptor gamma (PPARγ) agonist and antidiabetic agent in humans that has been investigated for its ability to reduce tumor cell growth. The purpose of this study was to det...